Viral Hepatitis Market Size, Share, Competitive Landscape and Trend Analysis Report

 Crafted for informed planning, this report explores the forces reshaping the viral hepatitis market and what they mean for business leaders.

 

 How Big Is The Viral Hepatitis Market In 2025?
 The viral hepatitis market size has grown steadily in recent years. It will grow from $16.21 billion in 2024 to $16.77 billion in 2025 at a compound annual growth rate (CAGR) of 3.4%. The growth in the historic period can be attributed to vaccine development, blood screening programs, antiviral drugs, global health initiatives.
 
 The viral hepatitis market size is expected to see steady growth in the next few years. It will grow to $19.71 billion in 2029 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to access to treatment, public health legislation, combination therapies, health equity initiatives. Major trends in the forecast period include personalized treatment plans, digital health tools, ai in disease monitoring, hepatitis c micro-elimination.
 
 Get your free sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=13028&type=smp
 
 What Are The Major Factors Driving The Viral Hepatitis Global Market Growth?
 The rising prevalence of hepatitis is expected to propel the growth of the viral hepatitis market going forward. Hepatitis is an infection of the liver caused by several infectious viruses and non-infectious substances, which can result in several medical issues. Hepatitis A, B, C, D and E are among the viruses that can cause viral hepatitis, which results in liver inflammation and damage. For instance, in April 2024, according to the European Centre for Disease Prevention and Control, a Sweden-based government health agency, there were 28,855 recorded cases of hepatitis B virus (HBV) infection across 30 EU/EEA Member States in 2022, an increase of 78% compared to 16,187 cases in 2021. Additionally, the number of cases in 2022, totaling 28,420, represents a crude rate of 8.5 cases per 100,000 people. Therefore, the rising prevalence of hepatitis will drive the viral hepatitis market.
 
 Viral Hepatitis Market Report Segmentation Analysis
 The viral hepatitismarket covered in this report is segmented — 
 
 1) By Disease Type: Hepatitis A; Hepatitis B; Hepatitis C; Other Disease Types
 2) By Diagnosis: Liver Biopsy; Blood Tests; Imaging Tests; Other Diagnosis
 3) By Treatment: Antiviral Drugs; Surgery; Vaccine; Immune Modulator Drugs; Other Treatments
 4) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
 5) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users
 
 Subsegments:
 1) By Hepatitis A: Acute Hepatitis A; Chronic Hepatitis A
 2) By Hepatitis B: Acute Hepatitis B; Chronic Hepatitis B; Hepatitis B Carrier
 3) By Hepatitis C: Acute Hepatitis C; Chronic Hepatitis C
 4) By Other Disease Types: Hepatitis D; Hepatitis E
 
 Emerging Trends And Strategic Opportunities In The Viral Hepatitis Market
 Companies operating in the viral hepatitis market are working on advancing new drugs and development to sustain their position in the market. Drug development and innovation boost scientific understanding by giving insights into disease mechanisms and accelerating the development of new treatments. For instance, in November 2022, Gilead Sciences Inc., a US-based biopharmaceutical company, announced that the Food and Drug Administration (FDA) had granted the supplemental new medicine application (sNDA) for Vemlidy (tenofovir alafenamide) 25 mg tablets as a once-daily medication to treat chronic hepatitis B virus (HBV) infection in children 12 years of age and older with compensated liver disease. The 24-week Phase 2 clinical trial results supported Vemlidy’s approval in this group of pediatric patients.
 
 What Are The Top Players Operating In The Viral Hepatitis Market?
 Major companies operating in the viral hepatitis market are Pfizer Inc., Johnson & Johnson Co, F Hoffmann-La Roche AG, Merck & Co., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Hetero Drugs Ltd., Eisai Co. Ltd., Boehringer Ingelheim Group, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy’s Laboratories, Zydus Lifescience Ltd., Glenmark Pharmaceuticals Ltd., Cipla Ltd., Torrent Pharmaceuticals Ltd., Otsuka Pharmaceutical Co. Ltd., Wockhardt Ltd.
 
 View the full viral hepatitis market report here:
 https://www.thebusinessresearchcompany.com/report/viral-hepatitis-global-market-report
 
 Which Region Holds The Largest Market Share In The Viral Hepatitis Market?
 North America was the largest region in the viral hepatitis market in 2024. The regions covered in viral hepatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company